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ABSTRACT
The aim of this study was to investigate the prevalence of hepatitis B virus (HBV) genotypes in Turkey.
Epidemiological and clinical data for 158 patients with acute HBV infection from 22 medical centres in
the period February 2001 to February 2002 were collected prospectively. HBV genotyping was based on
analysis of restriction fragment length polymorphisms and nested PCR. There were 59 female and
99 male patients, with a mean age of 34.2 ± 15.6 years. The most common probable transmission route
was blood contact in 63 (41.1%) cases, but was unknown in 78 (49.4%) cases. The mean alanine
aminotransferase level was 1718 ± 1089 IU ⁄L. Four of the 158 patients (2.5%) died because of fulminant
hepatitis. One year after discharge, 11 (10.6%) of 103 cases were positive for hepatitis B surface antigen
(HBsAg) and 80 (77.7%) were positive for anti-HBsAg. Genotype determination was unsuccessful in
11 cases because of a negative PCR; genotype D was found in the remaining 147 cases. The results
suggested that acute HBV infection constitutes a signiﬁcant health problem in Turkey and that genotype
D is predominant.
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INTRODUCTION
Hepatitis B virus (HBV) infection is a global
health problem, with an estimated 400 million
being chronic carriers of the virus [1]. HBV is
associated with acute and chronic hepatitis, liver
cirrhosis and hepatocellular carcinoma [2]. HBV
strains were classiﬁed originally into six different
genotypes, namely HBV genotypes A–F [3], but
two new genotypes, G and H, have been reported
recently [4,5]. Previous studies have shown char-
acteristic geographical distributions of different
HBV genotypes [6–8]; however, few data are
available regarding the distribution of HBV gen-
otypes in acute hepatitis B patients [9], partic-
ularly in the Turkish population. The aim of this
study was, therefore, to investigate the prevalence
of HBV genotypes in Turkey, as well as the
epidemiology, clinical course and outcome for
patients with acute HBV infections.
MATERIALS AND METHODS
Patients
Consecutive adult patients (n ¼ 158) with acute HBV infec-
tion who were admitted to 22 medical centres in Turkey
between February 2001 and February 2002 were included
prospectively in the study. The medical centres were repre-
sentative of all the geographical regions of the country. Acute
HBV infection was deﬁned by the presence of positive
hepatitis B surface antigen (HBsAg) and anti-Hepatitis B core
(HBc) IgM in patients with an acute onset of alanine
aminotransferase (ALT) elevation (more than twice the
normal upper limit; see below). None of the patients had a
previous history of liver disease, or reported any other causes
of liver injury (e.g., alcohol-, metabolite- or drug-induced
injury) or heart failure. Epidemiological and clinical data
were obtained prospectively during the ﬁrst week after the
onset of viral hepatitis (initial visit) and after 6 and
12 months. The possible transmission route of HBV, with
regard to blood contact, sexual, or horizontal transfer (e.g.,
the presence of HBV in close contacts), was investigated at
the initial examination. If the probable method of transmis-
sion could not be established, it was recorded as unknown.
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Biochemistry and serology
Liver biochemical tests, including albumin (normal range,
3.5–5 g ⁄dL), ALT (7–46 IU ⁄L), aspartate aminotransferase
(8–46 IU ⁄L), alkaline phosphatase (95–280 IU ⁄L), gamma-
glutamyltranspeptidase (7–49 IU ⁄L) and total bilirubin
(0.1–1.5 mg ⁄dL) levels, were done for all patients at initial
examination and during the follow-up at each institution.
Serological markers for hepatitis viruses were tested at each
institution during ﬁrst evaluation with commercially available
kits (Axsym; Abbott Laboratories, North Chicago, IL, USA)
for HBsAg, Hepatitis B early antigen (HBeAg), anti-HBeAg,
anti-HBc IgM, anti-HBc IgG, anti-HBsAg, anti-hepatitis A
virus (anti-HAV) (IgM and IgG), anti-hepatitis C virus (anti-
HCV), and anti-hepatitis D virus (anti-HDV) (IgM + IgG).
Genotyping of HBV
Serum samples from each subject were taken at ﬁrst examina-
tion and stored at ) 70 C until they were studied. HBV DNA
was isolated with a High Pure Viral Nucleic Acid kit (Roche
Diagnostics, Mannheim, Germany), according to the manufac-
turer’s instructions. In brief, 200 lL of serum were used for
DNA extraction, and 50 lL of elution buffer were used to elute
the DNA. An aliquot (5 lL) of HBV DNA eluate was then
added to 45 lL of reaction mix (containing 200 mM of each
nucleotide triphosphate, 0.4 mM of primers HBV-1 and HBV-2
[10] (Table 1), 1.5 mM MgCl2, 75 mM Tris-HCl, 20 mM
(NH4)2SO4, and 1.25 U Taq polymerase). PCR ampliﬁcation
comprised 40 cycles of 1 min at 94 C, 1 min at 55 C, and
2 min at 72 C. PCR amplicons were separated by electro-
phoresis on an agarose 1.5% w ⁄v gel, stained with ethidium
bromide, and visualised under UV light. Standard procedures
for reducing contamination were followed strictly.
The six major genotypes of HBV, i.e., A, B, C, D, E and F,
were recognised by analysis of the restriction fragment length
polymorphisms (RFLPs) created by digestion with AvaII and
DpnII of an ampliﬁed segment of the pre-S region as described
previously [10]. If genotype determination was not successful
by this method, a second method [11] was used in which the
HBV genome was ampliﬁed by nested PCR, ﬁrst with the
universal primers HBV-1 and S1-2, followed by ampliﬁcation
with mixtures containing type-speciﬁc inner primers (BD1:
type D-speciﬁc sense; BE1: type E-speciﬁc sense; BF1: type
F-speciﬁc sense; B2R: types D- to F-speciﬁc antisense). PCR
products were separated by electrophoresis on an agarose 3%
w ⁄v gel, stained with ethidium bromide, and visualised under
UV light. HBV genotypes were determined by identifying the
genotype-speciﬁc DNA bands (c. 119 bp, 167 bp and 97 bp for
genotypes D, E and F, respectively). This method did not allow
subtypes of genotype D to be identiﬁed.
Data in the text and tables are expressed as means ± stand-
ard deviation (SD). Differences between groups were exam-
ined by v2 and Fisher’s exact test. A p value of < 0.05 was
considered to be signiﬁcant.
RESULTS
Of 158 patients with acute HBV infection, 59 were
females and 99 were males (female ⁄male ¼ 0.59)
with a mean age of 34.2 ± 15.6 years (Table 2). All
patients were native residents of Turkey.
Although the HBV transmission route remained
unidentiﬁed in 49.4% of the patients, the most
common probable transmission route was blood
contact (41.1%), following recent surgery, dental
treatment, tooth extraction or body piercing,
followed by heterosexual transmission (Table 2).
Neither homosexual transmission nor a history of
intravenous drug use was documented for any
patient. The vast majority (154 ⁄ 158) of patients
had symptomatic and icteric infection. All
patients had elevated ALT levels (i.e., more than
twice the normal upper limit). The mean ALT,
aspartate aminotransferase and total bilirubin
levels were 1718 ± 1089 IU ⁄L, 1266 ± 806 IU ⁄L
and 11.3 ± 7.8 mg ⁄dL, respectively (Table 2).
Of the 158 patients, 74 were positive for HBeAg
and 60 were positive for anti-HBeAg on ﬁrst
examination. One (0.6%) patient was serologically
positive for HDV, and one patient (0.6%) had
HCV infection. Of 109 patients investigated,
102 (93.6%) were positive for anti-HAV IgG.
Four (2.5%) of the patients died because of
fulminant hepatitis. Six months after the initial
evaluation, 103 patients came for re-examination;
of these, only patients who were positive for
anti-HBc IgG, with or without HBsAg (n ¼ 31),
were invited for follow-up after a further
6 months. Overall, HBsAg, isolated anti-HBc
IgG, and anti-HBs positive rates were 10.6%,
11.7% and 77.7%, respectively, in control pa-
tients. There was no signiﬁcant difference in the
spontaneous HBsAg clearance rate according to
the HBeAg status (HBeAg-positive ⁄ anti-HBe-
negative) determined at the ﬁrst diagnosis of
HBV infection (90.2% vs. 83.3%). All HBsAg
carriers, except one, had normal ALT values at
ﬁnal follow-up.
Genotype determination was unsuccessful in
11 cases because of a negative PCR; therefore,
the HBV genotypes were investigated for
Table 1. Primer sequences used for HBV genotyping by
PCR-RFLP and nested PCR
HBV-1 5¢-TCACCATATTCTTGGGAACAAGA-3¢ (nt 2823–2845, sense)
HBV-2 5¢-TTCCTGAACTGGAGCCACCA-3¢ (nt 80–61, antisense)
S1-2 5¢-CGAACCACTGAACAAATGGC-3¢ (nt 685–704, antisense)
BD1 5¢-GCCAACAAGGTAGGAGCT-3¢ (nt 2979–2996, type D-speciﬁc, sense)
BE1 5¢-CACCAGAAATCCAGATTGGGACCA-3¢ (nt 2955–2978,
type E-speciﬁc, sense)
BF1 5¢-GYTACGGTCCAGGGTTACCA-3¢ (nt 3032–3051,
type F-speciﬁc, sense)
B2R 5¢-GGAGGCGGATYTGCTGGCAA-3¢ (nt 3078–3097,
types D- to F-speciﬁc, antisense)
Y represents a nucleotide that could be either a C or a T.
nt, nucleotide.
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147 patients. Genotype D was recognised in
129 serum samples on the basis of RFLP patterns.
There was no amplicon in 13 samples, while ﬁve
samples yielded inconclusive RFLP patterns.
Fig. 1 shows the RFLP patterns observed follow-
ing analysis of the pre-S region of HBV from
serum samples. Subtype D2 was found in 122
(94.6%) of 129 patients with genotype D, with
subtype D1 in ﬁve (3.9%) and D2 + deletion in
two (1.5%) cases. For the remaining 18 patients,
the genotypes were determined by nested PCR,
with genotype D being found in all cases.
DISCUSSION
The present study showed that blood exposure is
still the major means of acquiring HBV infection
in Turkey. Heterosexual contact was the second
most important transmission route (8.2% of
patients), but this percentage was below the
reported rates for other countries in Europe [9].
It is possible that sexual transmission was under-
reported because of social pressure. Intravenous
drug use is an important risk factor for transmis-
sion of HBV and HCV, but no drug use was
identiﬁed in the present study. Acute HBV infec-
tion is generally a self-limited disease, but four
patients in the study had fulminant hepatitis
characterised by encephalopathy and coagulopa-
thy, accompanied by deterioration in liver func-
tion, including elevated bilirubin levels. All four
of these patients died because of complications.
The overall mortality rate was 2.5%.
In Turkey, an area of intermediate endemicity,
the prevalence of HBV is highly variable in
different geographical regions within the country,
but HBV carriage is estimated at c. 6% in western
parts of Turkey, rising to 12.5–14.3% in eastern
and southeastern Turkey. High rates of HBsAg at
6 and 12 months after acute infection were detec-
ted in this study, possibly reﬂecting this geo-
graphical difference. However, the number of
follow-up patients was small. Discharged patients
who feel well do not usually present for follow-
up, which may affect the apparent carriage rate of
HBsAg. These patients should be monitored, as
the spontaneous clearance of HBsAg can be seen
later. There was no signiﬁcant difference in the
spontaneous HBsAg clearance rate according to
HBeAg status (HBeAg-positive ⁄HBeAg-negative)
determined at the ﬁrst diagnosis of HBV infection.
This study also demonstrated some character-
istics of infections with other hepatitis viruses,
such as HAV, HCV and HDV. Most of the adult
patients were immune to HAV infection. In early
studies, the prevalence of HDV infection was
reported as 23.9% in chronic HBV carriers, and
the delta coinfection was detected in 20 (8.4%) of
237 patients [12], but in the present study, the rate
of delta coinfection was only 0.6%. In Turkey, the
Table 2. Characteristics of patients









Age (years) 34.2 ± 15.6 33.9 ± 15.4 32.9 ± 15.4
Female ⁄male 59:99 (0.59) 29:45 (0.64) 19:41 (0.46)
Probable transmission route
Unknown 78 (49.4%) 36 (48.7%) 32 (53.3%)
Blood contact 65 (41.1%) 28 (37.8%) 25 (41.7%)
Heterosexual 13 (8.2%) 9 (12.2%) 2 (3.3%)
Horizontal 2 (1.3%) 1 (1.3%) 1 (1.7%)
ALT (IU ⁄L) 1718 ± 1089 1772.7 ± 1082.2 1681.8 ± 113.4
AST (IU ⁄L) 1266 ± 806 1337 ± 798.3 1171.3 ± 751.7
Total bilirubin (mg ⁄dL) 11.3 ± 7.8 11.3 ± 7.7 10.6 ± 7.7
Died 4 2 2
There was no signiﬁcant difference for all parameters between HBeAg-positive and anti-HBeAg-negative patients
(p > 0.05).
ALT, alanine aminotransferase; AST, aspartate aminotransferase.
Fig. 1. Examples of RFLP patterns obtained by analysis of
the pre-S region of HBV from serum samples.
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incidence of delta hepatitis is decreasing, especi-
ally in the western parts of the country, but it is
common in eastern and southeastern Turkey [13].
Interestingly, patients with delta coinfection lived
in eastern parts of Turkey. The prevalence of
chronic HCV infection was reported to be 1.5% in
Turkey in 1994 [14], but was found to be 0.6% in
the present study; the difference may be associ-
ated with regular screening of blood donations
since 1996, or may reﬂect the small size of the
study population used to determine HCV preval-
ence.
Eight genotypes (A–H) of HBV have now been
described [3–5]. In brief, genotypes B and C are
prevalent in Asia and the Far East, while geno-
type A is prevalent in northwestern Europe,
North America and Africa. Genotype D predom-
inates in the Mediterranean area and India [15],
while genotype E circulates in sub-Saharan Africa
[8]. Genotype F is found in Central and South
America. Genotype G has been reported from
France and North America [5]. Genotype H has
been described only recently, and its distribution
is not yet understood [4]. The distribution of HBV
genotypes in patients with acute HBV infection in
Turkey has not been reported previously, but in
this study, the most common genotype was
genotype D, in agreement with previous data
derived from patients with chronic HBV infection
in the same geographical region [6,8,15].
Previous studies have reported a correlation
between HBV genotypes and HBeAg clearance
[16–18], cirrhosis [18,19], hepatocellular carci-
noma [18–21], and response to antiviral therapy
[22–24]. Mayerat et al. [25] found that genotype A
was more common among patients with chronic
HBV infection, whereas genotype D was more
prevalent among patients with resolving acute
HBV infection, suggesting that HBV genotype D
was associated with a lower rate of chronic HBV
infection; however, Thakur et al. [26] concluded
that genotype D was associated with more severe
liver disease and may predict the occurrence of
hepatocellular carcinoma in young Indian pa-
tients. Erhardt et al. [23] reported that the rate of
interferon-induced HBeAg seroconversion was
lower among patients with genotype D than
among those with genotype A (6% vs. 37%). In
the present study, the relationship between HBV
genotypes and the outcome of acute HBV infec-
tion was inconclusive because only genotype D
was detected.
The present study used RFLP analysis to
classify HBV genotypes. RFLP is a simple method
that can be applied easily in clinical diagnostic
laboratories. In 18 serum samples, the genotype
could not be detected by PCR-RFLP analysis, but
could be determined by nested PCR, reﬂecting the
fact that nested PCR is c. 1000-fold more sensitive
than PCR-RFLP. There was no detectable rela-
tionship between subtypes and the outcome of
HBV infection. However, it is clear that acute
HBV infection constitutes a signiﬁcant health
problem in Turkey. The Turkish goverment
implemented a universal HBV immunisation
programme in 2000 [27], and it is hoped that
routine vaccination may protect adults from acute
HBV infection.
HEPATITIS STUDY GROUP
E. Aribas (Konya); F. Sirmatel (Gaziantep); C. Ayaz (Diyarba-
kir); M. F. Ozsoy, S. Cavuslu (Istanbul); R. Turkyilmaz,
E. Tutuncu (Ankara); M. Sunbul, S. Esen, D. Turan (Samsun);
A. Akbulut, M. Cihangiroglu (Elazig); B. Aygen, O. Yildiz
(Kayseri); G. Usluer, E. D. Kartal (Eskisehir); H. Irmak,
O. Evirgen (Van); N. Tulek, M. A. Yetkin (Ankara); I Dokmetas,
M. Bakir (Sivas); O. Ozgenc (Izmir); M. Parlak, E. Parlak
(Erzurum); I. Koksal, R. Caylan (Trabzon); I. Sencan (Duzce);
T. Yamazhan, S. Ulusoy (Izmir); Z. Akcam, G. Yayli (Isparta);
G. Ersoz, A. Kaya (Mersin); N. Saltoglu, Y. Tasova (Adana);
Y. Ersoy (Malatya); D. Kilic, S. Kaygusuz (Kirikkale).
ACKNOWLEDGEMENTS
This work was supported by a grant from Roche Pharmaceu-
ticals, Turkey. This study was presented in part at the 42nd
Interscience Conference on Antimicrobial Agents and Chemo-
therapy, San Diego, USA.
REFERENCES
1. Lee WM. Hepatitis B virus infection. N Engl J Med 1997;
337: 1733–1745.
2. Chen DS. From hepatitis to hepatoma: lessons from type B
viral hepatitis. Science 1993; 262: 369–370.
3. Okamoto H, Tsuda F, Sakugawa H et al. Typing hepatitis B
virus by homology in nucleotide sequence: comparison of
surface antigen subtypes. J Gen Virol 1988; 69: 2575–2583.
4. Arauz-Ruiz P, Norder H, Robertson BH, Magnius LO.
Genotype H: a new Amerindian genotype of hepatitis B
virus revealed in Central America. J Gen Virol 2002; 83:
2059–2073.
5. Stuyver L, De Gendt S, Van Geyt C et al. A new genotype
of hepatitis B virus: complete genome and phylogenetic
relatedness. J Gen Virol 2000; 81: 67–74.
6. Chu CJ, Lok AS. Clinical signiﬁcance of hepatitis B virus
genotypes. Hepatology 2002; 35: 1274–1276.
7. Norder H, Hammas B, Lee SD et al. Genetic relatedness of
hepatitis B viral strains of diverse geographical origin and
540 Clinical Microbiology and Infection, Volume 10 Number 6, June 2004
 2004 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 10, 537–541
natural variations in the primary structure of the surface
antigen. J Gen Virol 1993; 74: 1341–1348.
8. Lindh M, Andersson AS, Gusdal A. Genotypes, nt 1858
variants, and geographic origin of hepatitis B virus—large-
scale analysis using a new genotyping method. J Infect Dis
1997; 175: 1285–1293.
9. Lindh M, Horal P, Norkrans G. Acute hepatitis B in
Western Sweden—genotypes and transmission routes.
Infection 2000; 28: 161–163.
10. Lindh M, Gonzalez JE, Norkrans G, Horal P. Genotyping
of hepatitis B virus by restriction pattern analysis of a pre-
S amplicon. J Virol Meth 1998; 72: 163–174.
11. Naito H, Hayashi S, Abe K. Rapid and speciﬁc genotyping
system for hepatitis B virus corresponding to six major
genotypes by PCR using type-speciﬁc primers. J Clin
Microbiol 2001; 39: 362–364.
12. Balik I, Onul M, Tekeli E, Caredda F. Epidemiology and
clinical outcome of hepatitis D virus infection in Turkey.
Eur J Epidemiol 1991; 7: 48–54.
13. Yurdaydin C, Bozkaya H, Gurel S et al. Famciclovir treat-
ment of chronic delta hepatitis. J Hepatol 2002; 37: 266–271.
14. Thomas DL, Mahley RW, Badur S, Palaoglu E, Quinn TC.
The epidemiology of hepatitis C in Turkey. Infection 1994;
22: 411–414.
15. Kao JH. Hepatitis B viral genotypes: clinical relevance and
molecular characteristics. J Gastroenterol Hepatol 2002; 17:
643–650.
16. Lindh M, Hannoun C, Dhillon AP, Norkrans G, Horal P.
Core promoter mutations and genotypes in relation to
viral replication and liver damage in East Asian hepatitis B
virus carriers. J Infect Dis 1999; 179: 775–782.
17. Orito E, Mizokami M, Sakugawa H et al. A case-control
study for clinical and molecular biological differences
between hepatitis B viruses of genotypes B and C. Japan
HBV Genotype Research Group. Hepatology 2001; 33: 218–
223.
18. Ding X, Mizokami M, Yao G et al. Hepatitis B virus
genotype distribution among chronic hepatitis B
virus carriers in Shanghai, China. Intervirology 2001; 44:
43–47.
19. Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes
correlate with clinical outcomes in patients with chronic
hepatitis B. Gastroenterology 2000; 118: 554–559.
20. Fujie H, Moriya K, Shintani Y et al. Hepatitis B virus
genotypes and hepatocellular carcinoma in Japan. Gastro-
enterology 2001; 120: 1564–1565.
21. Orito E, Ichida T, Sakugawa H et al. Geographic distribu-
tion of hepatitis B virus (HBV) genotype in patients with
chronic HBV infection in Japan. Hepatology 2001; 34: 590–
594.
22. Kao JH, Wu NH, Chen PJ, Lai MY, Chen DS. Hepatitis B
genotypes and the response to interferon therapy. J Hepatol
2000; 33: 998–1002.
23. Erhardt A, Reineke U, Blondin D et al. Mutations of the
core promoter and response to interferon treatment in
chronic replicative hepatitis B. Hepatology 2000; 31: 716–
725.
24. Buti M, Cotrina M, Valdes A et al. Is hepatitis B virus
subtype testing useful in predicting virological response
and resistance to lamivudine? J Hepatol 2002; 36:
445–446.
25. Mayerat C, Mantegani A, Frei PC. Does hepatitis B virus
(HBV) genotype inﬂuence the clinical outcome of HBV
infection? J Viral Hepatol 1999; 6: 299–304.
26. Thakur V, Guptan RC, Kazim SN, Malhotra V, Sarin SK.
Proﬁle, spectrum and signiﬁcance of HBV genotypes in
chronic liver disease patients in the Indian subcontinent.
J Gastroenterol Hepatol 2002; 17: 165–170.
27. Van Damme P. Hepatitis B: vaccination programmes in
Europe—an update. Vaccine 2001; 19: 2375–2379.
Leblebicioglu et al. Acute HBV infection: epidemiology and genotyping 541
 2004 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 10, 537–541
